Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
CalciMedica, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies that target calcium-dependent pathways to address both acute and chronic health challenges. The company’s lead candidate, CM4620, aims to alleviate severe muscle cramps associated with sickle cell disease, underscoring its focus on meeting critical unmet medical needs. With a robust proprietary technology platform and an expanding pipeline of novel calcium modulators, CalciMedica is well-positioned for significant growth. Backed by an experienced management team and key strategic partnerships, the company presents a compelling investment opportunity within the biopharmaceutical sector.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$2.17
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 11, 2026 | $-0.33 | $-0.45 | Miss -36.4% | $-0.45 | $0 | $0 | — | 1D Pre-4.1% | On-Day-0.2% | 1D Post-5.7% |
Q ended Mar 31, 2026 Reported May 12, 2026 | $-0.28 | $0.30 | Beat +207.1% | $0.30 | $0 | $0 | — | 1D Pre-6.0% | On-Day+6.6% | 1D Post+9.5% |
Q ended Dec 31, 2025 Reported Mar 3, 2026 | $-0.41 | $-0.69 | Miss -68.3% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $0 |
| $0 |
| — |
| 1D Pre-1.8% |
| On-Day+14.4% |
| 1D Post+7.5% |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-0.41 | $-0.52 | Miss -26.8% | — | $0 | $0 | — | 1D Pre+4.9% | On-Day+4.0% | 1D Post-3.3% |